



Crossmark

Kirsty Meddings
Product Manager

Thursday 23rd February 2017



What is Crossmark

A button and a set of metadata that informs readers about

- **Publication status** (current, updated, retracted)
- Funding information
- Authors' ORCIDs
- Publication history
- Rights or licensing information
- And much more...

Publication status



erratum
corrigendum
correction
withdrawal
retraction
new edition
expression of concern
partial retraction
removal
addendum
clarification

The Chilling Effect: How Do Researchers React to Controversy?

Joanna Kempner*

Rutgers University, Department of Sociology and Institute for Health, Health Care Policy and Aging Research, New Brunswick, New Jersey, United States of America

Funding: This research was supported by the Robert Wood Johnson Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The author has declared that no competing interests exist.

Academic Editor: Peter Singer, University of Toronto, Canada

Citation: Kempner J (2008) The chilling effect: How do researchers react to controversy? PLoS Med 5(11): e222. doi:10.1371/journal.pmed.0050222

ABSTRACT

Background

Can political controversy have a “chilling effect” on the production of new science? This is a timely concern, given how often American politicians are accused of undermining science for political purposes. Yet little is known about how scientists react to these kinds of controversies.

Methods and Findings

Drawing on interview ($n = 30$) and survey data ($n = 82$), this study examines the reactions of scientists whose National Institutes of Health (NIH)-funded grants were implicated in a highly publicized political controversy. Critics charged that these grants were “a waste of taxpayer money.” The NIH defended each grant and no funding was rescinded. Nevertheless, this study finds that many of the scientists whose grants were criticized now engage in self-censorship. About half of the sample said that they now remove potentially controversial words from their



IUCrJ

ISSN 2052-2525

CHEMISTRY | CRYSTENG

Keywords: Editorial; crystal engineering.

Crystal engineering and IUCrJ

Gautam R. Desiraju*

Solid State and Structural Chemistry Unit, Indian Institute of Science, Bangalore 560 012, India. *Correspondence e-mail: gautam.desiraju@gmail.com

Crystal engineering has grown over time, with its practitioners now seeking specific answers to specialized questions. How does a molecular crystal nucleate and then grow? Can its structure be predicted computationally? Can one design a crystal structure with knowledge-based inputs? Can a crystal structure be considered as a collection of modular entities which represent its microcosms? What properties are characteristic of the crystal as a whole rather than of its constituent molecules? Can these properties be designed and is property design different from structure design? Can one predict if a given compound will have polymorphs and pseudopolymorphs? Can one design the structures of multi-component crystals in which each component is a solid when taken separately under ambient conditions? All these issues connect through the structural landscape of crystals and the exploration of this landscape, that is crystallization. The subject of crystal engineering covers not only purely organic solids but also organometallics and more



Document is current

Any future updates will be listed below

Crystal engineering and IUCrJ

Crossref DOI link: <https://doi.org/10.1107/s2052252515024100>

Published: 2016-01-01

Update policy: https://doi.org/10.1107/cm_01

> Authors




> More Information

ORIGINAL RESEARCH ARTICLE

Front. Bioeng. Biotechnol., 20 January 2016 | <http://dx.doi.org/10.3389/fbioe.2016.00001>



Voice Pathology Detection Using Modulation Spectrum-Optimized Metrics

 **Laureano Moro-Velázquez***,  **Jorge Andrés Gómez-García** and  **Juan Ignacio Godino-Llorente**

Center for Biomedical Technology, Universidad Politécnica de Madrid, Madrid, Spain


There exist many acoustic parameters employed for pathological assessment tasks, which have served as tools for clinicians to distinguish between normophonic and pathological voices. However, many of these parameters require an appropriate tuning in order to maximize its efficiency. In this work, a group of new and already proposed modulation spectrum (MS) metrics are optimized considering different time and frequency ranges pursuing the maximization of efficiency for the detection of pathological voices. The optimization of the metrics is performed simultaneously in two different voice databases in order to identify what tuning ranges produce a better generalization. The

and Biotechnology | Bioinformatics and Computational Biology

RESEARCH TOPIC
Applications in biomedicine

Check for updates


CrossMark

 **Updates are available**
Corrigendum dated 2016-08-24

Click to view Corrigendum:
<https://doi.org/10.3389/fbioe.2016.00067>

Voice Pathology Detection Using Modulation Spectrum-Optimized Metrics
Crossref DOI link: <https://doi.org/10.3389/fbioe.2016.00001>
Published:
Update policy: <https://doi.org/10.3389/crossmark-policy>

▶ Authors

 [About CrossMark](#)

ce Pat
pectrum

reano Moro-V
Biomedical Tec

xist many ac
as tools for cl
er, many of th


cy. In this work, a group of new and already proposed modulation spectrum (MS) metrics
imized considering different time and frequency ranges pursuing the maximization of
y for the detection of pathological voices. The optimization of the metrics is performed


lation

Godino-Llorent

which have
voices.
imize its



BUY ARTICLE 



Cloning, expression, crystallization and preliminary X-ray crystallographic analysis of aspartyl aminopeptidase from the *apeB* gene of *Pseudomonas aeruginosa*

S. Natarajan and R. Mathews

Aminopeptidases (APs) are a group of exopeptidases that catalyze the removal of amino acids from the N-termini of proteins and peptides. The APs are ubiquitous in nature and are of critical biological and medical importance because of their key role in protein degradation. *Pseudomonas aeruginosa* aspartyl aminopeptidase (PaAAP), which is encoded by the *apeB* gene, was expressed in *Escherichia coli*, purified and crystallized using the microbatch method. A preliminary structural study has been performed using the X-ray crystallographic method. The PaAAP crystal diffracted to 2.0 Å resolution and belonged to the rhombohedral space group *H3*, with unit-cell parameters $a = b = 133.6$, $c = 321.2$. The unit-cell volume of the crystal is compatible with the presence of four monomers in the asymmetric unit, with a corresponding Matthews coefficient V_M of $2.95 \text{ \AA}^3 \text{ Da}^{-1}$ and a solvent content of 58.3%.



Keywords: *Pseudomonas aeruginosa*; aspartyl aminopeptidase.

[Read article](#)

[Correction](#)

[Similar articles](#)

search IUcr Jo

ve edito

IZATION COM

(12). F68, 20

/10.1107/S17

UY ARTICLE

analysis

a

S. Nata

Aminop

from the

critical t

Pseudor

express

study ha

resolutio

321.2. 7

unit, wit

Keywo

Read a

ollow Acta C


UCr Journals


The IU

GO

nced search

thods.



 **Retraction**
Retraction dated 2012-11-01

Click to view Retraction:
<https://doi.org/10.1107/s1744309112039875>

Cloning, expression, crystallization and preliminary X-ray crystallographic analysis of aspartyl aminopeptidase from theapeBgene ofPseudomonas aeruginosa


Crossref DOI link: <https://doi.org/10.1107/s1744309111054388>

Published: 2012-02-01

Update policy: https://doi.org/10.1107/cm_01

> Authors

> More Information

 Crossref

[About CrossMark](#)

What constitutes a status update?

A change significant enough to affect the crediting or interpretation of the work

Allowed status update types

addendum

clarification

correction

corrigendum

erratum

expression_of_concern

new_edition

new_version

partial_retraction

removal

retraction

withdrawal

CrossMark



Document is current

Any future updates will be listed below

A preliminary study of cryosphere service function and value evaluation

Crossref DOI link: <https://doi.org/10.1016/j.accre.2015.11.004>

Published: 2015-09

Update policy: https://doi.org/10.1016/elsevier_cm_policy

› Authors

› Funding

› License Information

› More Information



[About CrossMark](#)

CrossMark



Document is current

Any future updates will be listed below

A preliminary study of cryosphere service function and value evaluation

Crossref DOI link: <https://doi.org/10.1016/j.accre.2015.11.004>

Published: 2015-09

Update policy: https://doi.org/10.1016/elsevier_cm_policy

▶ Authors


▶ Funding

▶ License Information

▶ More Information



[About CrossMark](#)



CrossMark ✕

✓ **Document is current**

Any future updates will be listed below


A preliminary study of cryosphere service function and value evaluation
Crossref DOI link: <https://doi.org/10.1016/j.accre.2015.11.004>
Published: 2015-09
Update policy: https://doi.org/10.1016/elsevier_cm_policy

▼ Authors

Xiao, Cun-De
Wang, Shi-Jin <http://orcid.org/0000-0002-4340-7420>
Qin, Da-He

➤ Funding

➤ License Information





Any future updates will be listed below

Generation of a cold pulsed beam of Rb atoms by transfer from a 3D magneto-optic trap

Crossref DOI link: <https://doi.org/10.1016/j.physleta.2016.07.022>

Published: 2016-08

Update policy: https://doi.org/10.1016/elsevier_cm_policy

> Authors

▼ Funding

Funding for this research was provided by:

Council of Scientific and Industrial Research

Department of Science and Technology, Government of Kerala

▼ License Information

[Text and Data Mining](#) valid from 2016-08-01

CrossMark



Any future updates will be listed below

Generation of a cold pulsed beam of Rb atoms by transfer from a 3D magneto-optic trap

Crossref DOI link: <https://doi.org/10.1016/j.physleta.2016.07.022>

Published: 2016-08

Update policy: https://doi.org/10.1016/elsevier_cm_policy

› Authors

▼ Funding

Funding for this research was provided by:

Council of Scientific and Industrial Research

Department of Science and Technology, Government of Kerala

▼ License Information

[Text and Data Mining](#) valid from 2016-08-01



CrossMark



Document is current

Any future updates will be listed below

Native valve disease in patients with non-valvular atrial fibrillation on warfarin or rivaroxaban

Crossref DOI link: <https://doi.org/10.1136/heartjnl-2015-308120>

Published: 2016-07-01

Update policy: <https://doi.org/10.1136/crossmarkpolicy>

> Authors

> Clinical Trials ^{BETA}



[About CrossMark](#)

Any future updates will be listed below

Native valve disease in patients with non-valvular atrial fibrillation on warfarin or rivaroxaban

Crossref DOI link: <https://doi.org/10.1136/heartjnl-2015-308120>

Published: 2016-07-01

Update policy: <https://doi.org/10.1136/crossmarkpolicy>

➤ Authors

▼ Clinical Trials ^{BETA}

Clinical trials referenced in this document

➤ [nct00403767 at ClinicalTrials.gov](#)

CrossMark

▼ Clinical Trials ^{BETA}

Clinical trials referenced in this document:

▼ nct00403767 at ClinicalTrials.gov

Documents that mention this clinical trial

Digoxin use in patients with atrial fibrillation and adverse cardiovascular outcomes: a retrospective analysis of the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF)

[https://doi.org/10.1016/s0140-6736\(14\)61836-5](https://doi.org/10.1016/s0140-6736(14)61836-5)

Efficacy and safety of rivaroxaban in patients with diabetes and nonvalvular atrial fibrillation: The Rivaroxaban Once-daily, Oral, Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF Trial)

<https://doi.org/10.1016/j.ahj.2015.07.006>

Native valve disease in patients with non-valvular atrial fibrillation on warfarin or rivaroxaban (Post-results)

<https://doi.org/10.1136/heartjnl-2015-308120>

Blood pressure control and stroke or bleeding risk in

CrossMark

▼ Clinical Trials ^{BETA}

Clinical trials referenced in this document:

▼ nct00403767 at ClinicalTrials.gov

Documents that mention this clinical trial

Digoxin use in patients with atrial fibrillation and adverse cardiovascular outcomes: a retrospective analysis of the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF)

[https://doi.org/10.1016/s0140-6736\(14\)61836-5](https://doi.org/10.1016/s0140-6736(14)61836-5)


Efficacy and safety of rivaroxaban in patients with diabetes and nonvalvular atrial fibrillation: The Rivaroxaban Once-daily, Oral, Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF Trial)

<https://doi.org/10.1016/j.ahj.2015.07.006>

Native valve disease in patients with non-valvular atrial fibrillation on warfarin or rivaroxaban (Post-results)


<https://doi.org/10.1136/heartjnl-2015-308120>

Blood pressure control and stroke or bleeding risk in




Articles

Digoxin use in patients with atrial fibrillation and adverse cardiovascular outcomes: a retrospective analysis of the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF)

Jeffrey B Washam, Pharm D, Susanna R Stevens, MS, Yuliya Lokhnygina, PhD, Prof Jonathan L Halperin, MD, Prof Günter Breithardt, MD, Prof Daniel E Singer, MD, Prof Kenneth W Mahaffey, MD, Prof Graeme J Hankey, MD, Scott D Berkowitz, MD, Christopher C Nessel, MD, Prof Keith A A Fox, MB ChB, Prof Robert M Califf, MD, Jonathan P Piccini, MD, Dr Manesh R Patel, MD  for the ROCKET AF Steering Committee and Investigators

Published Online: 05 March 2015

 89


DOI: [http://dx.doi.org/10.1016/S0140-6736\(14\)61836-5](http://dx.doi.org/10.1016/S0140-6736(14)61836-5) |  CrossMark



THE LANCET

Articles


Digoxin use in patients with atrial fibrillation and adverse cardiovascular outcomes: a retrospective analysis of the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF)

Jeffrey B Washam, Pharm D, Susanna R Stevens, MS, Yuliya Lokhnygina, PhD, Prof Jonathan L Halperin, MD, Prof Günter Breithardt, MD, Prof Daniel E Singer, MD, Prof Kenneth W Mahaffey, MD, Prof Graeme J Hankey, MD, Scott D Berkowitz, MD, Christopher C Nessel, MD, Prof Keith A A Fox, MB ChB, Prof Robert M Califf, MD, Jonathan P Piccini, MD, Dr Manesh R Patel, MD  for the ROCKET AF Steering Committee and Investigators

Published Online: 05 March 2015

Altmetric 89

DOI: <http://dx.doi.org/10.1016/S0140-673>



THE LANCET

Online First Current Issue All Issues


Search

< Previous Article

Volume

Articles

Digoxin use in patients with atrial fibrillation and adverse cardiovascular outcomes: a retrospective analysis of the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF)

Jeffrey B Washam, Pharm D, Susanna R Breithardt, MD, Prof Daniel E Singer, MD, Christopher C Nessel, MD, Prof Keetal Patel, MD  for the ROCKET AF Study Group

Published Online: 05 March 2015

CrossMark

▼ Clinical Trials ^{BETA}

Clinical trials referenced in this document:

▼ nct00403767 at ClinicalTrials.gov

Documents that mention this clinical trial

Digoxin use in patients with atrial fibrillation and adverse cardiovascular outcomes: a retrospective analysis of the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF)

[https://doi.org/10.1016/s0140-6736\(14\)61836-5](https://doi.org/10.1016/s0140-6736(14)61836-5)

Efficacy and safety of rivaroxaban in patients with diabetes and nonvalvular atrial fibrillation: The Rivaroxaban Once-daily, Oral, Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF Trial)

<https://doi.org/10.1016/j.ahj.2015.07.006>

Native valve disease in patients with non-valvular atrial fibrillation on warfarin or rivaroxaban (Post-results)

Digoxin use in atr

▼ More Information

[Publication:](#) IUCrJ

[Content type:](#) research papers

Peer review

Peer reviewed: Yes

Review process: Single blind

Publication history

Received: 24 December 2015

Accepted: 18 February 2016

Published online: 9 March 2016

[Supplementary materials:](#) This article has supporting information

Copyright and licencing

[Copyright:](#) © 2016 Karol Nasset al.

[Licence:](#) Creative Commons Attribution (CC-BY)

Machine access

Crossref REST API

<http://api.crossref.org>



```
→ ↻ ⓘ api.crossref.org/works?filter=has-clinical-trial-number:true

{
  "status": "ok",
  "message-type": "work-list",
  "message-version": "1.0.0",
  "message": {
    "facets": {},
    "total-results": 7637,
    "items": [
      {
        "indexed": {
          "date-parts": [
            [
              2016,
              11,
              1
            ]
          ],
          "date-time": "2016-11-01T18:17:18Z",
          "timestamp": 1478024238414
        },
        "reference-count": 75,
        "publisher": "National Institute for Health Research",
        "issue": "7",
        "license": [
          {
            "URL": "http://www.nationalarchives.gov.uk/doc/non-c
```

Reference lists




cite with
certainty

A Comprehensive Survey of Retracted Articles from the Scholarly Literature
Michael L. Grieneisen, Minghua Zhang

References

Abstract
Introduction
Materials and Methods
Results
Discussion
Supporting Information
Acknowledgments
Author Contributions
References
Reader Comments (1)
Media Coverage (0)
Figures

-  1. Cokol M, Iossifov I, Rodriguez-Esteban R, Rzhetsky A (2007) How many scientific papers should be retracted? *EMBO Rep* 8: 422–423. doi: 10.1038/sj.embor.7400970
[View Article](#) • [PubMed/NCBI](#) • [Google Scholar](#)
2. Steen RG (2011) Retractions in the medical literature: Who is responsible for scientific integrity? *AMWA J* 26: 2–8.
[View Article](#) • [PubMed/NCBI](#) • [Google Scholar](#)
-  3. Titus SL, Wells JA, Rhoades LJ (2008) Repairing research integrity. *Nature* 453: 980–982. doi: 10.1038/453980a
[View Article](#) • [PubMed/NCBI](#) • [Google Scholar](#)
4. Fanelli D (2009) How many scientists fabricate and falsify research? A systematic review and meta-analysis of survey data. *PLoS One* 4: e5738. doi: 10.1371/journal.pone.0005738
[View Article](#) • [PubMed/NCBI](#) • [Google Scholar](#)
-  5. Budd JM, Sievert ME, Schultz TR, Scoville C (1999) Effects of article retraction on citation and practice in medicine. *Bull Med Libr Assoc* 87: 437–443.
[View Article](#) • [PubMed/NCBI](#) • [Google Scholar](#)
6. Korpela KM (2010) How long does it take for the scientific literature to purge itself of fraudulent material? The Breuning case revisited. *Curr Med Res Opin* 26: 843–847. doi: 10.1185/03007991003603804
[View Article](#) • [PubMed/NCBI](#) • [Google Scholar](#)

Online reading environments

- Crossmark button on publisher copy of PDF
- Opportunities: ReadCube, Papers, Utopia, Mendeley, etc.
 - Enhance the PDF and display publication update notification
 - Notify users across all the channels available



Crossmark Best Practices

- Comprehensive deposit of publisher metadata
- Proper display of Crossmark button above or close to the title of the article
- Timely deposits of publication updates



Current Content = published in the past two years.

If you already participate

Upgrade to v2.0!

- New design buttons
- Mobile-friendly, responsive pop up box
- Widely-compatible code (no js)
- v1.5 not supported after March 2017

How?

- Replace snippet of code in your landing pages with 2.0 code from <https://www.crossref.org/get-started/crossmark/>
- Choose shape and size of button from Crossref CDN
 - <http://crossmark.crossref.org/widget/v2.0/readme.html>



Latest numbers

- 4.5 million Crossmark deposits
- 370 publishers
- 43,000 status updates
 - 1,500 retractions
 - 41,000 corrections
- 2.5 million DOIs with additional metadata

Thank you

www.crossref.org/services/crossmark/

kmeddings@crossref.org

